|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2000-9-19
|
|
pubmed:abstractText |
Animal studies have indicated that the use of syngeneic dendritic cells that have been transfected ex vivo with DNA for tumor-specific antigen results in tumor regression and decreased number of metastases. Additional studies have also suggested the possibility to modulate the dendritic cells in vivo either by 'naked' DNA immunization or by injecting replication-deficient viral vectors that carry the tumor-specific DNA. Using the prostate- specific membrane antigen (PSMA) as a target molecule, we have initiated a clinical trial for immunotherapy of prostate cancer. The primary objective of the study was to determine the safety of the PSMA vaccine after repeated intradermal injections.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD86,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Neoplasm,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Surface,
http://linkedlifedata.com/resource/pubmed/chemical/CD86 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Carboxypeptidases,
http://linkedlifedata.com/resource/pubmed/chemical/Glutamate Carboxypeptidase II,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, DNA,
http://linkedlifedata.com/resource/pubmed/chemical/glutamate carboxypeptidase II, human
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
0302-2838
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
38
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
208-17
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:10895014-Adenoviridae,
pubmed-meshheading:10895014-Aged,
pubmed-meshheading:10895014-Antigens, CD,
pubmed-meshheading:10895014-Antigens, CD86,
pubmed-meshheading:10895014-Antigens, Neoplasm,
pubmed-meshheading:10895014-Antigens, Surface,
pubmed-meshheading:10895014-Carboxypeptidases,
pubmed-meshheading:10895014-Combined Modality Therapy,
pubmed-meshheading:10895014-Glutamate Carboxypeptidase II,
pubmed-meshheading:10895014-Humans,
pubmed-meshheading:10895014-Immunization,
pubmed-meshheading:10895014-Male,
pubmed-meshheading:10895014-Membrane Glycoproteins,
pubmed-meshheading:10895014-Middle Aged,
pubmed-meshheading:10895014-Neoplasm Metastasis,
pubmed-meshheading:10895014-Plasmids,
pubmed-meshheading:10895014-Prostatic Neoplasms,
pubmed-meshheading:10895014-Vaccines, DNA
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a phase I/II clinical trial.
|
|
pubmed:affiliation |
American Foundation for Biological Research, Rockville, MD 20852, USA. mincheffm@netscape.net
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II,
Clinical Trial, Phase I
|
